價(jià)格 | ¥297 | ¥497 | ¥828 |
包裝 | 2mg | 5mg | 10mg |
最小起訂量 | 1mg |
發(fā)貨地 | 上海 |
更新日期 | 2024-12-12 |
中文名稱:化合物 ISCK03 | 英文名稱:ISCK03 |
CAS:945526-43-2 | 品牌: TargetMol |
產(chǎn)地: 美國(guó) | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
純度規(guī)格: 98.23% | 產(chǎn)品類別: 抑制劑 |
貨號(hào): T3452 |
名稱 | ISCK03 |
描述 | ISCK03 is a selective SCF/c-Kit inhibitor. |
細(xì)胞實(shí)驗(yàn) | To determine any cytotoxic effects of ISCK03 on 501mel cells, MTT assays are performed with various doses of ISCK03 (1, 5, 10 μM). 501mel cells are cultured with SCF alone (50 ng/mL) or SCF with ISCK03 for 48 h[1]. |
激酶實(shí)驗(yàn) | ATP is dispensed into 384-well plates, chemical compounds (ISCK03: 2.5, 5, 10, 100 μM) are added by replicative plate, and recombinant human c-kit protein is added for the kinase reaction. Following a 45-min incubation at 37°C, the development reaction is carried out for 40 min at room temperature. After the reaction is stopped, the coumrain and fluorescein fluorescence-emission signals are detected[1]. |
體外活性 | Pretreatment of 501mel cells with ISCK03 inhibits SCF-induced c-kit phosphorylation dose dependently. ISCK03 also inhibits p44/42 ERK mitogen-activated protein kinase (MAPK) phosphorylation, which is known to be involved in SCF/c-kit downstream signaling. However ISCK03 does not inhibit hepatocyte growth factor (HGF)-induced phosphorylation of p44/42 ERK proteins[1]. ISCK03, a tyrosine kinase inhibitor specific to KIT, prevents survival of CCDC26-KD cells under low-serum conditions. All treated cells exhibits sensitivity to ISCK03 in a dose-dependent manner. The survival of KD cells is suppressed to the same level as that of non-KD cells after ISCK03 treatment. On the contrary, ISCK03 treatment has limited effects on the growth of control K562 and KD clone 3–4 cells under high-serum concentration conditions[2]. |
體內(nèi)活性 | Oral administration of ISCK03 induces the dose-dependent depigmentation of newly regrown hair which is reversed with cessation of ISCK03 treatment. The topical application of ISCK03 promotes the depigmentation of UV-induced hyperpigmented spots. Fontana-Masson staining analysis shows epidermal melanin is diminished in spots treated with ISCK03[1]. |
存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : 50 mg/mL (140.66 mM) |
關(guān)鍵字 | inhibit | ISCK03 | SCFR | c-Kit | CD117 | Inhibitor | ISCK-03 | ISCK 03 |
相關(guān)產(chǎn)品 | Imatinib | Gilteritinib | Axitinib | Sorafenib tosylate | Lenvatinib mesylate | Regorafenib | Pazopanib | Dasatinib | Sorafenib | Pexidartinib | Imatinib Mesylate | Regorafenib monohydrate |
相關(guān)庫(kù) | 抑制劑庫(kù) | 經(jīng)典已知活性庫(kù) | 已知活性化合物庫(kù) | 激酶抑制劑庫(kù) | 干細(xì)胞分化化合物庫(kù) | NO PAINS 化合物庫(kù) | 膜蛋白靶向化合物庫(kù) | 酪氨酸激酶分子庫(kù) | 表型篩選靶點(diǎn)鑒定庫(kù) |
成立日期 | 2013-04-18 (12年) | 注冊(cè)資本 | 566.265100萬(wàn)人民幣 |
員工人數(shù) | 100-500人 | 年?duì)I業(yè)額 | ¥ 1億以上 |
主營(yíng)行業(yè) | 天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù) | 經(jīng)營(yíng)模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢價(jià) |
VIP1年
|
青島愷潤(rùn)生物醫(yī)藥科技有限公司
|
2025-02-07 | |
詢價(jià) |
VIP5年
|
山東沃德森生物科技有限公司
|
2025-02-06 | |
詢價(jià) |
VIP3年
|
陜西締都新材料有限公司
|
2024-12-18 | |
¥2009.90 |
VIP2年
|
上海阿拉丁生化科技股份有限公司
|
2024-11-29 |